CXCR4靶向PET/CT在早期系统性硬化症相关间质性肺病中的应用:一项前瞻性概念验证研究
结果显示SSc患者肺门/纵隔淋巴结、纤维化肺区域及左心室心肌的[68Ga]Pentixafor摄取均显著高于对照组;随访中肺病进展者左心室摄取显著高于未进展者。结论提示CXCR4靶向PET/CT或可显示早期SSc-ILD的炎症/重塑活动。
要点
- SSc患者淋巴结、纤维化肺区及左心室[68Ga]Pentixafor摄取均显著高于对照组。
- 随访肺病进展者左心室摄取显著高于未进展者。
- 纤维化肺区摄取在进展者中呈数值升高但未达统计学显著。
核心结论
- CXCR4靶向PET/CT可能显示早期SSc-ILD的炎症和/或重塑活动。
研究设计与样本
- 对照组为巨细胞动脉炎患者,采集疾病进展随访数据。
主要发现
- SSc患者淋巴结中位TBR为3.5(IQR 2.7-4.3),对照组为1.6(1.3-2.0),p<0.0001。
- SSc患者下肺叶中位TBR为2.3(1.6-2.8),对照组为0.8(0.7-1.0),p<0.0001。
- SSc患者左心室中位TBR为2.0(1.4-2.4),对照组为1.3(1.1-1.5),p=0.0178。
- 随访肺病进展者左心室TBR为2.5(2.1-3.3),未进展者为1.5(1.3-2.1),p=0.0283。
- 纤维化肺区进展者TBR为2.8(2.2-3.3),未进展者为1.7(1.1-2.8),p=0.1535。
临床怎么用
- 在早期SSc-ILD中可考虑用[68Ga]Pentixafor PET/CT评估CXCR4相关炎症/重塑活动。
- 左心室[68Ga]Pentixafor摄取或有助于提示随访肺病进展风险。
局限性
- 对照组为巨细胞动脉炎患者,非健康对照。
- 纤维化肺区进展者与未进展者摄取差异未达统计学显著(p=0.1535)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Distinguishing active inflammatory or remodeling-associated processes from irreversible fibrosis in systemic sclerosis remains challenging using conventional imaging modalities. The tracer [68Ga]Pentixafor targets the C-X-C motif chemokine receptor 4 (CXCR4) which is expressed on leukocytes. Uptake of [68Ga]Pentixafor may provide complementary biological information on CXCR4-associated inflammatory and remodeling activity. METHODS: This prospective cohort study included patients with early SSc (disease duration ≤ 5 years) and preexisting interstitial lung disease. All patients underwent [68Ga]Pentixafor-PET/CT imaging. Normalized [68Ga]Pentixafor uptake was quantified using the target-to-background ratio (TBR). Follow-up data on disease progression was collected. A control group comprised patients with giant cell arteritis. RESULTS: Twelve patients with SSc were included. The highest [68Ga]Pentixafor uptake was observed in the hilar and mediastinal lymph nodes, in fibrotic lung regions, and in the left ventricular myocardium. In all three regions, a significantly higher [68Ga]Pentixafor uptake was measured in SSc compared to controls (median TBR of lymph nodes 3.5 [IQR 2.7 - 4.3] vs 1.6 [1.3 - 2.0] p < 0.0001; inferior lung lobes 2.3 [1.6 - 2.8] vs 0.8 [0.7 - 1.0], p < 0.0001; and left ventricle 2.0 [1.4 - 2.4] vs 1.3 [1.1 - 1.5], p = 0.0178). Patients who developed progressive lung disease during follow-up showed a higher [68Ga]Pentixafor uptake compared to non-progressive patients reaching statistical significance in the left ventricle (TBR of progressive vs non-progressive patients: 2.5 (2.1 - 3.3) vs 1.5 (1.3 - 2.1), p = 0.0283) and showing a numerical increase in fibrotic lung regions (2.8 (2.2 - 3.3) vs 1.7 (1.1 - 2.8), p = 0.1535). CONCLUSION: These findings provide proof-of-concept evidence that CXCR4-targeted PET/CT may visualize biologically active inflammatory and/or remodeling processes in early-stage SSc-ILD.
引用
- Gernert M, Schmalzing M, Labinsky H, et al. CXCR4-targeted PET/CT in early systemic sclerosis-associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activity. Eur J Nucl Med Mol Imaging. 2026. PMID: 42301424. doi:10.1007/s00259-026-08000-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。